nitrazepam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 1945 146-22-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nitrazadon
  • nitrazepam
  • neozepam
  • nitrodiazepam
A benzodiazepine derivative used as an anticonvulsant and hypnotic.
  • Molecular weight: 281.27
  • Formula: C15H11N3O3
  • CLOGP: 2.32
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 1
  • TPSA: 87.28
  • ALOGS: -3.97
  • ROTB: 2

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.03 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.02 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 78 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.86 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.13 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 26 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.215 Moderate 0.73
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.676 Moderate 0.73
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 79.983 10^-6 cm/s Moderate 0.73
dh-clint Dog hepatocyte intrinsic clearance 11.402 uL/min/10^6 cells Moderate 0.73
dppb Dog plasma protein binding (% unbound) 22.790 % Moderate 0.73
fcs-ppb Fetal calf serum protein binding (% unbound) 35.040 % Moderate 0.73
herg hERG pIC50 4.698 pIC50 Moderate 0.73
hh-clint Human hepatocyte intrinsic clearance 4.375 uL/min/10^6 cells Moderate 0.73
hlm-clint Human liver microsomal intrinsic clearance 8.166 uL/min/mg protein Moderate 0.73
hppb Human plasma protein binding (% unbound) 19.780 % Moderate 0.73
kinase-safety-class ACVR2B,CDK5,EIF2AK3,GRK2,MAPK10,MAPK7,PDK1,PDK2,PDK4,TTK 10
kinase-selectivity-class GRK2,TTK 2
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.032 Moderate 0.73
mh-clint Mouse hepatocyte intrinsic clearance 9.376 Moderate 0.73
mppb Mouse plasma protein binding (% unbound) 20.150 Moderate 0.73
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.286 Moderate 0.73
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 28.660 % Moderate 0.73
rh-clint Rat hepatocyte intrinsic clearance 21.777 uL/min/10^6 cells Moderate 0.73
rh-fuinc Rat hepatocyte fraction unbound in incubation 78.330 % Moderate 0.73
rppb Rat plasma protein binding (% unbound) 20.370 % Moderate 0.73
solubility-dd Solubility at pH 7.4 in DMSO 94.842 uM Moderate 0.73

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Enthesopathy 413.20 26.93 112 9959 9292 90609084
Tongue disorder 365.67 26.93 105 9966 10755 90607621
Tenosynovitis 364.75 26.93 112 9959 14455 90603921
Blood parathyroid hormone decreased 344.77 26.93 103 9968 12113 90606263
Panniculitis 331.84 26.93 104 9967 14354 90604022
Skin necrosis 311.61 26.93 103 9968 16838 90601538
Red blood cell sedimentation rate 303.99 26.93 76 9995 4582 90613794
Granuloma skin 301.15 26.93 90 9981 10590 90607786
Rheumatoid nodule 294.01 26.93 103 9968 20063 90598313
Tendonitis 291.95 26.93 104 9967 21268 90597108
Drug eruption 250.89 26.93 107 9964 35300 90583076
Ulcer 248.41 26.93 104 9967 32778 90585598
Hypercalcaemia 244.35 26.93 104 9967 34136 90584240
Basal cell carcinoma 243.53 26.93 103 9968 33286 90585090
Skin ulcer 203.62 26.93 103 9968 49972 90568404
Alanine aminotransferase abnormal 176.05 26.93 51 10020 5375 90613001
Aspartate aminotransferase increased 160.07 26.93 114 9957 102823 90515553
Rash pruritic 156.09 26.93 103 9968 82111 90536265
Fear of injection 149.43 26.93 50 10021 8465 90609911
Alanine aminotransferase increased 145.87 26.93 114 9957 118224 90500152
Red blood cell sedimentation rate increased 131.89 26.93 93 9978 82502 90535874
C-reactive protein abnormal 130.12 26.93 110 9961 127319 90491057
Loss of personal independence in daily activities 121.84 26.93 109 9962 135996 90482380
Drug tolerance decreased 110.21 26.93 59 10012 32071 90586305
Granuloma 95.50 26.93 33 10038 6152 90612224
Overdose 92.02 26.93 100 9971 157609 90460767
Inflammation 91.81 26.93 106 9965 178486 90439890
Joint injury 87.52 26.93 51 10020 32613 90585763
Chest discomfort 84.69 26.93 90 9981 138275 90480101
Musculoskeletal disorder 80.38 26.93 42 10029 21727 90596649
C-reactive protein increased 79.03 26.93 99 9972 181290 90437086
Blood pressure systolic increased 75.70 26.93 58 10013 58287 90560089
Erythema 73.82 26.93 108 9963 229138 90389238
Rheumatoid lung 71.61 26.93 24 10047 4079 90614297
Suicide attempt 68.61 26.93 61 10010 75338 90543038
Psoriatic arthropathy 66.98 26.93 103 9968 228232 90390144
Drug tolerance 61.70 26.93 33 10038 17883 90600493
Intellectual disability 54.96 26.93 15 10056 1271 90617105
Osteomyelitis 50.63 26.93 34 10037 27812 90590564
Angioplasty 48.42 26.93 14 10057 1463 90616913
Gastric disorder 45.08 26.93 34 10037 33350 90585026
Toxicity to various agents 42.81 26.93 97 9974 287749 90330627
Synovitis 42.41 26.93 105 9966 329647 90288729
Therapeutic response decreased 42.29 26.93 51 10020 89678 90528698
Blood creatinine increased 41.98 26.93 54 10017 101332 90517044
Retinal vein occlusion 40.86 26.93 14 10057 2542 90615834
Therapy non-responder 40.50 26.93 62 10009 136642 90481734
Therapeutic product effect incomplete 37.76 26.93 73 9998 193823 90424553
Peripheral vascular disorder 37.60 26.93 17 10054 6414 90611962
Vasoconstriction 36.32 26.93 10 10061 875 90617501
Limb injury 35.84 26.93 29 10042 31479 90586897
Rheumatoid arthritis 35.11 26.93 104 9967 362510 90255866
Intentional overdose 34.26 26.93 47 10024 93787 90524589
Choking 32.78 26.93 19 10052 12014 90606362
Drug abuse 32.74 26.93 43 10028 82304 90536072
Crepitations 32.44 26.93 17 10054 8835 90609541
Transient ischaemic attack 31.67 26.93 31 10040 43145 90575231
Pulmonary congestion 31.25 26.93 22 10049 19411 90598965
Peripheral swelling 29.64 26.93 107 9964 412999 90205377
Systemic lupus erythematosus 29.50 26.93 3 10068 361893 90256483
Retinal exudates 29.19 26.93 8 10063 688 90617688
Altered state of consciousness 27.65 26.93 25 10046 31507 90586869
Drug hypersensitivity 27.46 26.93 113 9958 463496 90154880
Aggression 27.11 26.93 23 10048 26645 90591731

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tenosynovitis 299.75 23.97 81 6705 4614 42609935
Enthesopathy 297.50 23.97 81 6705 4747 42609802
Tongue disorder 257.17 23.97 74 6712 5309 42609240
C-reactive protein abnormal 229.47 23.97 77 6709 9184 42605365
Synovitis 204.37 23.97 81 6705 15486 42599063
Alanine aminotransferase abnormal 183.83 23.97 56 6730 4888 42609661
Tendonitis 178.67 23.97 65 6721 9829 42604720
Psoriatic arthropathy 118.09 23.97 64 6722 24903 42589646
Aspartate aminotransferase increased 101.96 23.97 90 6696 77073 42537476
Loss of personal independence in daily activities 101.76 23.97 75 6711 49741 42564808
Treatment failure 94.84 23.97 79 6707 62545 42552004
Red blood cell sedimentation rate 94.74 23.97 24 6762 1056 42613493
Granuloma skin 92.73 23.97 24 6762 1151 42613398
Drug hypersensitivity 91.56 23.97 95 6691 99294 42515255
Blood parathyroid hormone decreased 84.76 23.97 24 6762 1619 42612930
Toxicity to various agents 80.17 23.97 136 6650 229000 42385549
Alanine aminotransferase increased 78.70 23.97 83 6703 88323 42526226
Panniculitis 78.05 23.97 24 6762 2157 42612392
Erythema 72.73 23.97 88 6698 108705 42505844
Rheumatoid nodule 70.56 23.97 24 6762 2971 42611578
Multiple-drug resistance 65.43 23.97 29 6757 7293 42607256
Drug intolerance 65.40 23.97 72 6714 80352 42534197
Skin necrosis 53.19 23.97 24 6762 6290 42608259
Contraindicated product administered 51.43 23.97 38 6748 25234 42589315
Suicide attempt 49.60 23.97 48 6738 46052 42568497
Intentional overdose 46.96 23.97 49 6737 51407 42563142
C-reactive protein increased 46.69 23.97 54 6732 63506 42551043
Drug eruption 41.00 23.97 32 6754 23043 42591506
Neuroleptic malignant syndrome 38.63 23.97 30 6756 21442 42593107
Cor pulmonale acute 38.23 23.97 9 6777 290 42614259
Measles 37.65 23.97 9 6777 310 42614239
Headache 36.83 23.97 102 6684 239267 42375282
Pneumonia aspiration 35.85 23.97 42 6744 50036 42564513
Dyspnoea 35.74 23.97 13 6773 442608 42171941
Hypersensitivity 35.02 23.97 50 6736 72320 42542229
Altered state of consciousness 34.38 23.97 32 6754 29227 42585322
Skin wrinkling 33.96 23.97 9 6777 473 42614076
Ulcer 31.83 23.97 24 6762 16417 42598132
Procedural failure 31.66 23.97 6 6780 65 42614484
Mobility decreased 31.09 23.97 33 6753 35273 42579276
Therapy non-responder 30.54 23.97 40 6746 53319 42561230
Hypercalcaemia 29.84 23.97 24 6762 18034 42596515
Rhabdomyolysis 29.40 23.97 48 6738 77971 42536578
Skin ulcer 28.16 23.97 27 6759 25574 42588975
Dystonia 27.75 23.97 20 6766 12770 42601779
Foreign body aspiration 27.47 23.97 7 6779 315 42614234
Basal cell carcinoma 26.97 23.97 25 6761 22708 42591841
Inflammation 26.94 23.97 30 6756 33817 42580732
Renal tubular acidosis 24.91 23.97 11 6775 2739 42611810
Rheumatoid lung 24.12 23.97 8 6778 916 42613633

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Enthesopathy 618.30 22.04 173 15897 12305 110560924
Tenosynovitis 572.80 22.04 173 15897 16110 110557119
Tongue disorder 537.88 22.04 160 15910 14138 110559091
Tendonitis 420.99 22.04 154 15916 25929 110547300
Alanine aminotransferase abnormal 357.71 22.04 106 15964 9228 110564001
Blood parathyroid hormone decreased 350.83 22.04 113 15957 12976 110560253
Panniculitis 335.41 22.04 114 15956 15468 110557761
Red blood cell sedimentation rate 326.67 22.04 87 15983 5127 110568102
Granuloma skin 313.02 22.04 100 15970 11183 110562046
Rheumatoid nodule 302.31 22.04 113 15957 20183 110553046
Skin necrosis 295.91 22.04 113 15957 21399 110551830
Drug eruption 227.27 22.04 124 15946 53535 110519694
Ulcer 223.36 22.04 114 15956 43002 110530227
Aspartate aminotransferase increased 220.75 22.04 184 15886 159752 110413477
C-reactive protein abnormal 219.07 22.04 168 15902 129527 110443702
Basal cell carcinoma 218.12 22.04 114 15956 45156 110528073
Hypercalcaemia 214.87 22.04 114 15956 46543 110526686
Loss of personal independence in daily activities 189.38 22.04 164 15906 149856 110423373
Alanine aminotransferase increased 185.17 22.04 177 15893 183596 110389633
Skin ulcer 184.45 22.04 115 15955 63530 110509699
Fear of injection 160.12 22.04 57 16013 8854 110564375
Rash pruritic 135.53 22.04 113 15957 97956 110475273
Psoriatic arthropathy 131.02 22.04 152 15918 196609 110376620
Erythema 119.06 22.04 177 15893 291270 110281959
Synovitis 111.27 22.04 166 15904 273926 110299303
Red blood cell sedimentation rate increased 101.53 22.04 87 15983 78215 110495014
C-reactive protein increased 97.16 22.04 138 15932 217781 110355448
Granuloma 96.13 22.04 40 16030 9450 110563779
Toxicity to various agents 92.78 22.04 211 15859 480344 110092885
Rheumatoid lung 90.66 22.04 31 16039 4273 110568956
Drug tolerance decreased 88.00 22.04 53 16017 27487 110545742
Musculoskeletal disorder 86.65 22.04 49 16021 22615 110550614
Inflammation 84.10 22.04 121 15949 193117 110380112
Joint injury 81.33 22.04 58 16012 39936 110533293
Overdose 80.07 22.04 131 15939 233663 110339566
Drug tolerance 77.65 22.04 41 16029 16544 110556685
Drug hypersensitivity 74.24 22.04 187 15883 453903 110119326
Therapy non-responder 64.79 22.04 96 15974 157211 110416018
Drug intolerance 63.91 22.04 165 15905 406347 110166882
Multiple-drug resistance 62.76 22.04 33 16037 13202 110560027
Suicide attempt 62.34 22.04 76 15994 103318 110469911
Treatment failure 61.66 22.04 129 15941 277105 110296124
Blood pressure systolic increased 58.34 22.04 66 16004 82925 110490304
Pneumonia aspiration 56.08 22.04 64 16006 81169 110492060
Altered state of consciousness 55.09 22.04 54 16016 57572 110515657
Chest discomfort 53.61 22.04 93 15977 173755 110399474
Gastric disorder 53.58 22.04 42 16028 33315 110539914
Intentional overdose 50.48 22.04 78 15992 132423 110440806
Angioplasty 48.66 22.04 16 16054 1955 110571274
Osteomyelitis 48.10 22.04 41 16029 36559 110536670
Contraindicated product administered 46.66 22.04 108 15962 248159 110325070
Neuroleptic malignant syndrome 44.44 22.04 38 16032 34021 110539208
Salivary hypersecretion 44.27 22.04 29 16041 17392 110555837
Dyspnoea 43.00 22.04 59 16011 1106813 109466416
Choking 42.97 22.04 27 16043 15083 110558146
Rhabdomyolysis 40.54 22.04 67 16003 120334 110452895
Rheumatoid arthritis 39.43 22.04 114 15956 299499 110273730
Asthenia 39.24 22.04 26 16044 688973 109884256
Limb injury 35.47 22.04 35 16035 37601 110535628
Pain in extremity 34.20 22.04 14 16056 487104 110086125
Intellectual disability 33.07 22.04 12 16058 1967 110571262
Psychiatric symptom 32.75 22.04 19 16051 9194 110564035
Therapeutic product effect incomplete 32.22 22.04 88 15982 223717 110349512
Measles 31.83 22.04 9 16061 662 110572567
Vasoconstriction 31.44 22.04 10 16060 1100 110572129
Peripheral vascular disorder 31.32 22.04 18 16052 8558 110564671
Retinal vein occlusion 31.11 22.04 14 16056 3993 110569236
Cor pulmonale acute 30.72 22.04 9 16061 751 110572478
Peripheral swelling 30.63 22.04 128 15942 403906 110169323
Dystonia 30.07 22.04 27 16043 25778 110547451
Drug abuse 29.88 22.04 74 15996 177337 110395892
Urinary retention 29.34 22.04 43 16027 69640 110503589
Delusion 27.97 22.04 25 16045 23730 110549499
Therapeutic response decreased 27.63 22.04 50 16020 96449 110476780
Crepitations 27.44 22.04 18 16052 10817 110562412
Sinusitis 27.39 22.04 5 16065 296683 110276546
Procedural failure 27.31 22.04 6 16064 155 110573074
Paraesthesia 26.99 22.04 4 16066 276517 110296712
Systemic lupus erythematosus 26.46 22.04 3 16067 254335 110318894
Product use in unapproved indication 25.28 22.04 17 16053 447360 110125869
Hepatic function abnormal 25.23 22.04 46 16024 89249 110483980
Foreign body aspiration 24.58 22.04 7 16063 528 110572701
Chest pain 24.55 22.04 12 16058 376363 110196866
Skin wrinkling 24.40 22.04 9 16061 1544 110571685
Loss of consciousness 24.18 22.04 73 15997 196233 110376996
Pruritus 23.53 22.04 30 16040 581530 109991699
COVID-19 22.90 22.04 4 16066 245056 110328173
Headache 22.54 22.04 211 15859 882166 109691063
Febrile neutropenia 22.38 22.04 9 16061 316758 110256471
Infusion related reaction 22.35 22.04 112 15958 381050 110192179
Abdominal pain 22.31 22.04 25 16045 512964 110060265
Retinal exudates 22.26 22.04 8 16062 1276 110571953
Hallucination, auditory 22.04 22.04 23 16047 26374 110546855

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05CD02 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Benzodiazepine derivatives
MeSH PA D000927 Anticonvulsants
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D006993 Hypnotics and Sedatives
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35623 anticonvulsant
CHEBI has role CHEBI:35717 sedative
CHEBI has role CHEBI:49103 drug metabolite
CHEBI has role CHEBI:50268 GABA modulator
CHEBI has role CHEBI:53784 antispasmodic drug

Related Drugs by ATC class:

N05CD Benzodiazepine derivatives 14 drugs
brotizolamcinolazepamdoxefazepamestazolamflunitrazepamflurazepamloprazolamlormetazepammidazolamnimetazepamquazepamremimazolam show all 14 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Myoclonic seizure indication 37356005
Insomnia indication 193462001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.11 acidic
pKa2 2.85 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR EC50 8 WOMBAT-PK KEGG DRUG
GABA-A receptor; anion channel Ion channel IC50 7.42 CHEMBL

External reference:

IDSource
N0000166923 NUI
D00531 KEGG_DRUG
C0028126 UMLSCUI
CHEBI:7581 CHEBI
CHEMBL13209 ChEMBL_ID
DB01595 DRUGBANK_ID
D009567 MESH_DESCRIPTOR_UI
4506 PUBCHEM_CID
2121 INN_ID
9CLV70W7HS UNII
7440 RXNORM
003484 NDDF
387449001 SNOMEDCT_US
78449007 SNOMEDCT_US

Pharmaceutical products:

None